Adult Immunization

The safety data used to update the Flublok label is from a study of more than 48 000 pregnant women across multiple flu seasons, according to Sanofi.

IDWeek 2024: Older adults vaccinated with BNT162b2 (Comirnaty) had approximately half the odds of developing long COVID vs unvaccinated adults, according to new data.

IDWeek2024: The nanoparticle influenza vaccine and combination flu-Covid-19 shot produced immunogenicity comparable to or higher than comparator vaccines.

V116 (CAPVAXIVE™) covers the serotypes responsible for approximately 84% of invasive pneumococcal disease cases in adults aged 50 years and older.

Essential health screenings and immunizations are declining among US adults. A new survey identified 7 issues that help drive the reduced rates.

Data on adults aged 60 years and older who received a single dose of the RSV vaccine indicate safety and reactogenicity consistent with the overall GSK phase 3 trial program.

Older adults hospitalized with RSV were older, more frail, and more likely to have respiratory comorbidities than those with influenza A or B, the study found.

COVID-19 vaccine myths of many types remain potent enough to raise public health experts' concerns about Americans' willingness to roll up sleeves this year.

Adults saying they don't need immunization this fall have received the vaccines in the past, survey authors report, suggesting a lingering misinformation effect.

Your daily dose of the clinical news you may have missed.

New report includes data on the safety and immunogenicity of the recently-approved PCV21 vaccine.

Immune responses for both vaccines were noninferior when given at the same visit compared with separate administration among adults aged 50 years and older.

The GSK reformulation induced acceptable immune responses for both influenza A and B strains, overcoming a setback earlier in the ability to successfully neutralize the latter.

The new data amend that from prelicensure trials, which did not include fair representation of older adults and others more vulnerable to severe RSV disease.

The Bridge Access Program allowed Americans who are uninsured or underinsured to receive COVID-19 vaccination at not cost and was ended abruptly last month.

Now that the WHO has declared a second mpox global emergency, you may want to brush up on knowledge of the disease and the 2024 outbreak.

Do you know the ACIP-preferred influenza vaccine for adults aged ≥65 yrs? The cut-off age for HPV vaccination? The time between the 2-dose mpox series? More, here.

The influenza/COVID-19 combination did not prove noninferior to the comparator flu vaccine against influenza B, the companies reported.

Of the 25 routine lab tests studied, none proved clinically useful for diagnosing COVID-19, even among participants with a high long COVID symptom burden.

RSVPreF induced strong neutralizing responses in immunocompromised adults aged 18 years and older in substudy B of the ongoing phase 3 MONET clinical trial.

Wyoming, Louisiana, and Oklahoma have the lowest percentage of population with shots in arms based on state population. Is your state among the other 7?

Your daily dose of the clinical news you may have missed.

The Advisory Committee on Immunization Practices' revisions prioritize vulnerable older adults and those at higher risk of severe infection.

This summary of updates to the ACIP 2024 Adult Vaccination recommendations includes 4 new vaccines and new formulations for COVID-19 and influenza shots.

Your daily dose of the clinical news you may have missed.

Ziyad Al-Aly, MD, and colleagues link 70% of the drop in cases to vaccine availability but caution the risk for long COVID remains significant.

The investigational live intranasal vaccine was safe and well-tolerated when given concomitantly with Fluzone HD and the combination outperformed the latter given by itself.

Data from a study performed during the first season the shot was available expand on clinical trial evidence and support the safety of RSVpreF, authors wrote.

The novel vaccination is recommended as an option for adults aged 65 years and older who have not received a pneumococcal conjugate vaccine.

The committee endorsed a universal recommendation for a single lifetime dose of RSV vaccine for adults aged ≥75 years and a risk-based recommendation for those aged 60 to 74 years.